Isomorphic Labs raises $5B to push AI-designed drugs into trials
The DeepMind spinout raised $5B led by Greenoaks and Sequoia to take its AI-designed oncology and immunology drug candidates into clinical trials, months after a $2.1B Series B.

Why it matters
- Isomorphic Labs raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital.
- The round follows a $2.1 billion Series B in May 2025 and marks the first fundraise since Demis Hassabis left his role as head of DeepMind to focus on drug discovery.
- Bloomberg reported the lab was seeking funding at a $50 billion valuation; Isomorphic did not disclose the figure.
- The company reported "positive preclinical results" in oncology and immunology and holds deals with Eli Lilly, Novartis, and Johnson & Johnson.
- Hassabis and John Jumper won the Nobel Prize in Chemistry for AlphaFold, which predicts protein 3D structure from genetic sequence.
Isomorphic Labs has raised $5 billion in a Series C round to move its AI-designed drug candidates into clinical trials. The round, co-led by Greenoaks and Sequoia Capital, lands just five months after the company closed a $2.1 billion Series B in May — a pace of fundraising that signals how much capital it takes to bridge the gap between a promising molecule and a human trial.
The scale matters. A $5 billion round would be a headline event for almost any software company. For a drug-discovery lab that has yet to run a clinical trial, it ranks among the largest private financings in biotech history, and it shows investors are willing to bet that AI can compress one of the most expensive, failure-prone pipelines in industry.
New investor Andreessen Horowitz joined the Series C, alongside every one of Isomorphic's existing backers. That list includes Alphabet's two venture arms, GV and Capital G, plus Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund. Isomorphic did not disclose the valuation for the round. Bloomberg reported earlier this month that the lab was seeking funding at a $50 billion valuation.
Who is Isomorphic Labs, and why did Google spawn it?
Isomorphic Labs is an AI drug-discovery platform that was spun out of Google's DeepMind in 2021. Its founding premise is that drug design is, at bottom, an information problem — and that the tools DeepMind built to solve protein structures can be turned toward inventing medicines.
The company builds what it calls a drug-design engine: a collection of simulation AI models that explore different areas of chemistry to help its scientists design drug candidates. The work builds directly on DeepMind's AlphaFold breakthrough, the system that predicts the 3D structure of a protein from nothing more than its genetic sequence. If you can predict how a protein folds, the reasoning goes, you can predict — and eventually design — the molecules that bind to it and change its behavior.
Takeaway: Isomorphic is the commercial follow-through on one of AI's clearest scientific wins, turning protein-structure prediction into a drug-design factory.
What has the engine actually produced?
The company said its program has yielded "positive preclinical results" in oncology and immunology. That is lab-and-animal-stage evidence, not human data — but in drug discovery, preclinical results are the price of admission for clinical trials, which is exactly where Isomorphic says it now wants to go.
Big pharma has already bought in. Isomorphic has struck deals with Eli Lilly, Novartis, and Johnson & Johnson, three of the largest drugmakers in the world. Those partnerships serve two purposes: they bring in revenue without diluting shareholders, and they give a young lab credibility in an industry where validation traditionally takes a decade.
Takeaway: The engine has pharma partners and early biology results, and the $5 billion is meant to carry both into human testing.
Why is Demis Hassabis's role change part of this story?
The Series C is Isomorphic's first fundraise since its founder and CEO, Demis Hassabis, left his position as head of DeepMind to focus on drug discovery. He also moved into a chairman role at DeepMind, handing day-to-day leadership of the famed AI lab to others while keeping a hand in it.
Hassabis is not a typical founder-CEO. He and John Jumper, then a director at DeepMind, won the Nobel Prize in Chemistry for the lab's work on AlphaFold. A Nobel laureate reallocating his full attention from one of the world's most influential AI labs to a drug-discovery startup is itself a statement about where he thinks the biggest near-term payoff of AI lies — not in chatbots, but in chemistry.
Takeaway: The most decorated figure in applied AI has now made drug discovery his only job, and investors just funded that bet at $5 billion.
Where does the money go?
The new capital has two stated uses. First, Isomorphic will continue developing its drug-design engine — improving the simulation models and expanding what the platform can predict and design. Second, the company plans to foray into more types of medicine, pushing beyond its current focus areas.
There is also an implied third use: clinical trials themselves. Running even a mid-stage trial program in oncology or immunology routinely costs hundreds of millions of dollars, and taking multiple candidates into the clinic simultaneously is a burn rate few startups can survive. The $5 billion gives Isomorphic the runway to fail at least sometimes — which, in drug development, is the realistic baseline.
Takeaway: The money funds better models, more disease areas, and — most expensively — the shift from preclinical promise to human data.
What's at stake for the AI-drug-discovery field?
Isomorphic's round lands at a moment when the AI-biotech thesis is under real scrutiny. Several high-profile AI drug-discovery companies have seen candidates stumble in clinical trials, and skeptics argue that designing molecules is the easy part — proving they work safely in humans remains a biology problem that no model can simulate away.
A $5 billion commitment at a reported $50 billion valuation is a counter-argument: that the AlphaFold lineage, combined with a simulation-first design engine and pharma partnerships, gives Isomorphic a better shot than the first wave of AI-drug startups. The company won't get to test that claim in the lab it just funded — it will get to test it in patients, which is the only venue that settles the question.
Takeaway: If Isomorphic's candidates succeed in clinical trials, AI drug design graduates from promising research to a repeatable industrial method; if they don't, the field's toughest skeptics get their evidence.
The next milestone to watch is straightforward: the first Isomorphic-designed drug candidate entering human trials, with oncology and immunology the likeliest starting points.
Original: isomorphiclabs.com
More from Sophie Lindqvist
Show full bio
Staff writer covering regulation, policy and their impact on artificial intelligence and machine learning at AI In Context.
749 articles
Related articles
- Isomorphic Labs raises $5 billion, its second mega-round in six months
- Isomorphic Labs Raises $5B as AI Drug Design Faces Trial Test
- INFevo Raises Over RMB 100M to Build AI Virtual Cells and Robotic Labs
- Proximal Ventures Closes $27.5M Debut Fund for AI Life Sciences
- Orakl Oncology raises $34 million to scale AI cancer predictions